玻璃体内注射雷珠单抗治疗早产儿视网膜病变后的无应答和复发情况
Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment.
作者信息
Chuluunbat Tsengelmaa, Chan R V Paul, Wang Nan-Kai, Lien Reyin, Chen Yen-Po, Chao An-Ning, Chen Kuan-Jen, Chen Tun-Lu, Hwang Yih-Shiou, Lai Chi-Chun, Wu Wei-Chi
出版信息
Ophthalmic Surg Lasers Imaging Retina. 2016 Dec 1;47(12):1095-1105. doi: 10.3928/23258160-20161130-03.
BACKGROUND AND OBJECTIVE
To evaluate the surgical outcome of type 1 retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) treatment.
PATIENTS AND METHODS
This was a prospective case series. Premature infants with treatment-requiring ROP who received IVR injections from 2013 to 2015 were included.
RESULTS
Twenty-two eyes of 12 children were included in the study. Complete resolution of ROP after a single IVR was noted in 73% of eyes. Retreatment was needed in 27% of eyes due to nonresponse to IVR (18%) or recurrence of ROP (9%). After that, all treated eyes (100%) demonstrated regressed ROP with attached retina. The median visual acuity was 0.3 LogMAR (range: 0 LogMAR to 0.8 LogMAR) with a mean follow-up of 25.2 months ± 6.8 months.
CONCLUSIONS
IVR is effective and well-tolerated for patients with treatment-requiring ROP. However, nonresponse to IVR or recurrence of ROP after IVR was noted in 27% of treated eyes and required additional treatment. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:1095-1105.].
背景与目的
评估玻璃体内注射雷珠单抗（IVR，商品名：Lucentis；基因泰克公司，美国加利福尼亚州南旧金山）治疗1型早产儿视网膜病变（ROP）的手术效果。
患者与方法
这是一项前瞻性病例系列研究。纳入2013年至2015年接受IVR注射治疗的需要治疗的ROP早产儿。
结果
12名儿童的22只眼纳入研究。73%的患眼在单次IVR治疗后ROP完全消退。27%的患眼因对IVR无反应（18%）或ROP复发（9%）需要再次治疗。此后，所有接受治疗的患眼（100%）ROP均消退，视网膜复位。平均随访25.2个月±6.8个月，平均视力为0.3 LogMAR（范围：0 LogMAR至0.8 LogMAR）。
结论
IVR治疗需要治疗的ROP患者有效且耐受性良好。然而，27%的患眼对IVR无反应或IVR治疗后ROP复发，需要进一步治疗。[《眼科手术、激光与视网膜影像》。2016；47：1095 - 1105。]
Zotero 插件